HOUT-17. A PRELIMINARY DATA REPORT ON A PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA

od Bota, Daniela, Chung, Jinah, Carrillo, Jose, Kong, Xiao-Tang, Fu, Beverly, Pretto, Chrystel, Strik, Ankie, Schijns, Virgil, Stathopoulos, Apostolos
Izdano u Neuro Oncol (2017)

ATIM-42. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: OS CORRELATIONS WITH INITIAL AND MAXIMUM CD4+T LYMPHOCYTE COUNT IN THE PERIPHERAL BL...

od Bota, Daniela, Taylor, Thomas, Xiao-Tang, Kong, Fu, Beverly, Alsharif, Mohamad, Pretto, Chrystel, Strik, Ankie, Schijns, Virgil, Stathopoulos, Apostolos
Izdano u Neuro Oncol (2019)

ET-54 IMMUNOTHERAPY BASED ON TUMOR TRANSPLANT ANTIGEN RECOGNITION EMERGES AS A PROMISING STRATEGY FOR RECURRENT GLIOBLASTOMA MULTIFORME (GBM) PATIENTS

od Schijns, Virgil, Pretto, Chrystel, Devillers, Laurent, Pierre, Denis, Hofman, Florence, Kruse, Carol, Chen, Thomas, Oertel, Joachim, Hantos, Peter, Bota, Daniela, Stathopoulos, Apostolos
Izdano 2014

Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation

od Stathopoulos, Apostolis, Pretto, Chrystel, Devillers, Laurent, Pierre, Denis, Hofman, Florence M., Kruse, Carol, Jadus, Martin, Chen, Thomas C., Schijns, Virgil E.J.C.
Izdano 2012

Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report

od Bota, Daniela A, Alexandru-Abrams, Daniela, Pretto, Chrystel, Hofman, Florence M, Chen, Thomas C, Fu, Beverly, Carrillo, Jose A, Schijns, Virgil EJC, Stathopoulos, Apostolos
Izdano u Perm J (2015)

Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators

od Stathopoulos, Apostolos, Pretto, Chrystel, Devillers, Laurent, Pierre, Denis, Hofman, Florence M., Epstein, Alan L., Farghadani, Hooman, Kruse, Carol A., Jadus, Martin R., Chen, Thomas C., Schijns, Virgil E.J.C.
Izdano 2012

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts

od Bota, Daniela A, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A, Kong, Xiao-Tang, Fu, Beverly D, Hsu, Frank PK, Schönthal, Axel H, Hofman, Florence M, Chen, Thomas C, Zidovetzki, Raphael, Pretto, Chrystel, Strik, Ankie, Schijns, Virgil EJC, Stathopoulos, Apostolos
Izdano u CNS Oncol (2018)

ATIM-28. PHASE 2 STUDY OF ERC1671 PLUS BEVACIZUMAB VS BEVACIZUMAB PLUS PLACEBO IN RECURRENT GBM INTERIM RESULTS AND CORRELATIONS WITH CD4+ T LYMPHOCYTE COUNTS

od Bota, Daniela A, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A, Kong, Xiao-tang, Beverly Fu, Dan, Hsu, Frank P K, Schönthal, Alex H, Hofman, Florence M, Chen, Thomas C, Zidovetzki, Raphael, Pretto, Chrystel, Strik, Ankie, Schijns, Virgil E J C, Stathopoulos, Apostolos
Izdano u Neuro Oncol (2018)

Therapeutic Immunization against Glioblastoma

od Schijns, Virgil E. J. C., Pretto, Chrystel, Strik, Anna M., Gloudemans-Rijkers, Rianne, Devillers, Laurent, Pierre, Denis, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A., Kong, Xiao-Tang, Fu, Beverly D., Hsu, Frank P. K., Hofman, Florence M., Chen, Thomas C., Zidovetzki, Raphael, Bota, Daniela A., Stathopoulos, Apostolos
Izdano u Int J Mol Sci (2018)